tavapadon – Lab DB

Pharmaceutical R&D

Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data

Teuku Ryan Apr 24, 2026 0

AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…

Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data

YOU MAY HAVE MISSED

TWiV 1287: Ancient herpesviruses and modern dementia

Johns Hopkins Researchers Discover How Fusion Genes Drive Rare Kidney Cancer Through Liquid Droplets

RNA breakthrough provides hope for thousands of untreatable diseases, including cystic fibrosis, muscular dystrophy and some cancers

Merck and Moderna’s cancer vaccine is customized for each patient’s tumor